TY - JOUR
T1 - REP1 deficiency causes systemic dysfunction of lipid metabolism and oxidative stress in choroideremia
AU - Cunha, Dulce Lima
AU - Richardson, Rose
AU - Tracey-White, Dhani
AU - Abbouda, Alessandro
AU - Mitsios, Andreas
AU - Horneffer-van der Sluis, Verena
AU - Takis, Panteleimon
AU - Owen, Nicholas
AU - Skinner, Jane
AU - Welch, Ailsa A
AU - Moosajee, Mariya
N1 - Funding Information:
The authors are thankful to Metabolon Inc., particularly Gregory A. Michelotti, for metabolome profiling and assistance with data analysis; Matthew Lewis and Caroline Sands from the MRC-NIHR National Phenome Centre, Imperial College London, for input on the lipidomics experiments; and Eduardo Lima Cunha for helping with figure preparation. This work was supported by Wellcome Trust (grant number 205174/Z/16/Z), NIH Research (NIHR) Rare Diseases Translational Research Collaboration Award, and the NIHR Biomedical Research Centre (BRC) at Moorfields and UCL Institute of Ophthalmology, Choroi-deremia Research Foundation USA, Fight for Sight UK, and Moorfields Eye Charity to MM. This work was also supported by the Medical Research Council and NIHR (grant no. MC_PC_12025), and infrastructure support was provided by the NIHR Imperial BRC.
Funding Information:
The authors are thankful to Metabolon Inc., particularly Gregory A. Michelotti, for metabolome profiling and assistance with data analysis; Matthew Lewis and Caroline Sands from the MRC-NIHR National Phenome Centre, Imperial College London, for input on the lipidomics experiments; and Eduardo Lima Cunha for helping with figure preparation. This work was supported by Wellcome Trust (grant number 205174/Z/16/Z), NIH Research (NIHR) Rare Diseases Translational Research Collaboration Award, and the NIHR Biomedical Research Centre (BRC) at Moorfields and UCL Institute of Ophthalmology, Choroideremia Research Foundation USA, Fight for Sight UK, and Moorfields Eye Charity to MM. This work was also supported by the Medical Research Council and NIHR (grant no. MC_PC_12025), and infrastructure support was provided by the NIHR Imperial BRC.
Publisher Copyright:
© 2021, Lima Cunha et al.
PY - 2021/5/10
Y1 - 2021/5/10
N2 - Choroideremia (CHM) is an X-linked recessive chorioretinal dystrophy caused by mutations in CHM, encoding for Rab escort protein 1 (REP1). Loss of functional REP1 leads to the accumulation of unprenylated Rab proteins and defective intracellular protein trafficking, the putative cause for photoreceptor, retinal pigment epithelium (RPE), and choroidal degeneration. CHM is ubiquitously expressed, but adequate prenylation is considered to be achieved, outside the retina, through the isoform REP2. Recently, the possibility of systemic features in CHM has been debated; therefore, in this study, whole metabolomic analysis of plasma samples from 25 CHM patients versus age- and sex-matched controls was performed. Results showed plasma alterations in oxidative stress-related metabolites, coupled with alterations in tryptophan metabolism, leading to significantly raised serotonin levels. Lipid metabolism was disrupted with decreased branched fatty acids and acylcarnitines, suggestive of dysfunctional lipid oxidation, as well as imbalances of several sphingolipids and glycerophospholipids. Targeted lipidomics of the chmru848 zebrafish provided further evidence for dysfunction, with the use of fenofibrate over simvastatin circumventing the prenylation pathway to improve the lipid profile and increase survival. This study provides strong evidence for systemic manifestations of CHM and proposes potentially novel pathomechanisms and targets for therapeutic consideration.
AB - Choroideremia (CHM) is an X-linked recessive chorioretinal dystrophy caused by mutations in CHM, encoding for Rab escort protein 1 (REP1). Loss of functional REP1 leads to the accumulation of unprenylated Rab proteins and defective intracellular protein trafficking, the putative cause for photoreceptor, retinal pigment epithelium (RPE), and choroidal degeneration. CHM is ubiquitously expressed, but adequate prenylation is considered to be achieved, outside the retina, through the isoform REP2. Recently, the possibility of systemic features in CHM has been debated; therefore, in this study, whole metabolomic analysis of plasma samples from 25 CHM patients versus age- and sex-matched controls was performed. Results showed plasma alterations in oxidative stress-related metabolites, coupled with alterations in tryptophan metabolism, leading to significantly raised serotonin levels. Lipid metabolism was disrupted with decreased branched fatty acids and acylcarnitines, suggestive of dysfunctional lipid oxidation, as well as imbalances of several sphingolipids and glycerophospholipids. Targeted lipidomics of the chmru848 zebrafish provided further evidence for dysfunction, with the use of fenofibrate over simvastatin circumventing the prenylation pathway to improve the lipid profile and increase survival. This study provides strong evidence for systemic manifestations of CHM and proposes potentially novel pathomechanisms and targets for therapeutic consideration.
U2 - 10.1172/jci.insight.146934
DO - 10.1172/jci.insight.146934
M3 - Article
C2 - 33755601
SN - 2379-3708
VL - 6
JO - JCI Insight
JF - JCI Insight
IS - 9
M1 - e146934
ER -